eluxadoline
eluxadoline: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.
eluxadoline evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could eluxadoline → ABBV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| AbbVie Inc. (ABBV) Reported 2015-05-27 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (1)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Primary endpoint: Change from baseline in stool consistency averaged over the 4-week Treatment Period
Frequently asked questions
Which companies have sourced relationships with eluxadoline?
eluxadoline has dated SEC/FDA relationship records for AbbVie Inc..
How many clinical trials involve eluxadoline?
BioSniper tracks 1 clinical trial involving eluxadoline.
What is eluxadoline's latest FDA decision?
The most recent tracked FDA decision for eluxadoline is Approval, dated May 27, 2015.